SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.495-3.3%1:48 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: End2War9/16/2025 11:24:34 AM
1 Recommendation

Recommended By
erippetoe

  Read Replies (1) of 1216
 
From PPS on X today (9/15):


Dr. Pat Soon-Shiong






@DrPatSoonShiong


The future is here. Cell therapy especially CAR-NK therapy is the next era of cancer care. Especially when you combine cell therapy w cytokines such as ANKTIVA. Amassing cancer killer cells
@ImmunityBio
Waldenstrom trial open at t.co


cancernetwork.com
Novel CD19 CAR-NK Therapy Yields Responses in Waldenstrom Macroglobulinemia
The CD19 t-haNK therapy alone and in combination with rituximab achieved complete responses and no significant toxicities in 2 patients with late-stage WM.


6:30 AM · Sep 15, 2025
·

24.7K
Views
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News